Definium Therapeutics reported earnings of -$ 0.46 per DFTX share on Nov 9, 2026, falling short of analysts' expectations by
| Report Date | Nov 9, 2026 |
|---|---|
| Forecasted EPS | -$ 0.56 |
| Earnings Per Share (Surprise) | -$ 0.46 (+$ 0.1029) |
| Last Year's EPS | -$ 0.53 |
| EPS YoY Change |
Out of the last 39 earnings reporting periods, Definium Therapeutics beat analysts’ expectations 8 times and fell short of expectations 14 time(s). Definium Therapeutics reported earnings per share of -$ 0.46 in the last report surpassing an estimated EPS of -$ 0.56 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 9, 2026 | -$ 0.56 | -$ 0.46 | -$ 0.78 | |
| Aug 6, 2026 | -$ 0.54 | -$ 1.44 | -$ 0.50 | |
| May 7, 2026 | -$ 0.47 | -$ 0.71 | -$ 0.35 | |
| Feb 26, 2026 | -$ 0.48 | -$ 0.51 | -$ 0.41 | |
| Nov 6, 2025 | -$ 0.52 | -$ 0.78 | -$ 0.27 | |
| Jul 31, 2025 | -$ 0.38 | -$ 0.50 | -$ 0.48 | |
| May 8, 2025 | -$ 0.36 | -$ 0.35 | -$ 1.14 | |
| Mar 6, 2025 | -$ 0.33 | -$ 0.41 | -$ 0.59 | |
| Nov 7, 2024 | -$ 0.28 | -$ 0.27 | -$ 0.53 | |
| Aug 13, 2024 | -$ 0.30 | -$ 0.48 | -$ 0.72 | |
| May 8, 2024 | -$ 0.66 | -$ 1.14 | -$ 0.51 | |
| Feb 28, 2024 | -$ 0.48 | -$ 0.59 | -$ 0.27 | |
| Nov 2, 2023 | -$ 0.65 | -$ 0.53 | -$ 0.56 | |
| Aug 3, 2023 | -$ 0.54 | -$ 0.72 | -$ 0.60 | |
| May 4, 2023 | -$ 0.41 | -$ 0.51 | -$ 0.60 | |
| Mar 9, 2023 | -$ 0.49 | -$ 0.27 | -$ 0.75 | |
| Nov 10, 2022 | -$ 0.58 | -$ 0.56 | -$ 0.90 | |
| Aug 11, 2022 | -$ 0.75 | -$ 0.60 | -$ 1.35 | |
| May 16, 2022 | -$ 0.75 | -$ 0.60 | -$ 0.57 | |
| Mar 28, 2022 | -$ 0.70 | -$ 0.75 | -$ 0.48 |
Definium Therapeutics’s stock was trading at $ 33.27 on Nov 8, 2026 a day before the last earnings report was released.Following the release of the earnings report, DFTX’s price increased to $ 34.64 on Nov 10, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 9, 2026 | -$ 0.46 | $ 33.27 | $ 34.64 | |
| Aug 6, 2026 | -$ 1.44 | $ 44.39 | $ 46.14 | |
| May 7, 2026 | -$ 0.71 | $ 23.42 | $ 22.05 | |
| Feb 26, 2026 | -$ 0.51 | $ 17.62 | $ 17.45 | |
| Nov 6, 2025 | -$ 0.78 | $ 11.53 | $ 11.70 | |
| Jul 31, 2025 | -$ 0.50 | $ 9.03 | $ 8.44 | |
| May 8, 2025 | -$ 0.35 | $ 6.59 | $ 6.15 | |
| Mar 6, 2025 | -$ 0.41 | $ 6.38 | $ 6.83 | |
| Nov 7, 2024 | -$ 0.27 | $ 6.75 | $ 8.49 | |
| Aug 13, 2024 | -$ 0.48 | $ 6.85 | $ 6.66 | |
| May 8, 2024 | -$ 1.14 | $ 9.55 | $ 9.12 | |
| Feb 28, 2024 | -$ 0.59 | $ 5.56 | $ 5.72 | |
| Nov 2, 2023 | -$ 0.53 | $ 2.49 | $ 3.09 | |
| Aug 3, 2023 | -$ 0.72 | $ 4.59 | $ 4.35 | |
| May 4, 2023 | -$ 0.51 | $ 3.69 | $ 3.41 | |
| Mar 9, 2023 | -$ 0.27 | $ 3.34 | $ 3.01 | |
| Nov 10, 2022 | -$ 0.56 | $ 2.41 | $ 2.89 | |
| Aug 11, 2022 | -$ 0.60 | $ 9.78 | $ 10.89 | |
| May 16, 2022 | -$ 0.60 | $ 11.70 | $ 11.61 | |
| Mar 28, 2022 | -$ 0.75 | $ 17.70 | $ 17.70 |
Definium Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, February 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Definium Therapeutics beat analysts’ expectations during the last earnings period by
